An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Phase of Trial: Phase III
Latest Information Update: 03 Apr 2018
At a glance
- Drugs Mirogabalin (Primary)
- Indications Fibromyalgia; Pain
- Focus Adverse reactions; Registrational
- Sponsors Daiichi Sankyo Inc
- 31 Aug 2017 According to a Daiichi Sankyo media release, the results from the global clinical development program consisting of several phase 3 clinical trials, including NEUCOURSE, REDUCER and ALDAY, will serve as the basis for potential regulatory submissions in various countries.
- 01 Jul 2017 This trial was completed in Slovenia (end date: 2017-04-19), according to European Clinical Trials Database.
- 30 Jun 2017 Status changed from active, no longer recruiting to completed, according to a Daiichi Sankyo media release.